共 50 条
- [31] A first-in-human (FIH) phase I study of IPH5301, an anti-CD73 monoclonal antibody (mAb), in patients with advanced solid tumors (AST) (CHANCES, NCT05143970)ANNALS OF ONCOLOGY, 2024, 35 : S682 - S683Beaufils, M.Mailliez, A.Sfumato, P.Vicier, C.Gross, M. ProvansalGuerin, M.Chanez, B.Kotecki, N.Widemann, A.Panzolato, S.Chammard, A. BoyerAndre, P.Paturel, C. L.Gouarne, C.Awada, A. H.Boher, J. M.Goncalves, A.
- [32] A phase 2, multiarm study of anti-CD47 antibody, magrolimab, in combination with docetaxel in patients with locally advanced or metastatic solid tumors.JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (06)Subbiah, VivekVaishampayan, Ulka N.Puri, SonamLin, LanjiaChao, MarkRamsingh, GiriKummar, ShivaaniStrauss, James F.Patel, Sandip P.
- [33] A first-in-human, phase 1/2a study of GI-102 (CD80-IL2v3) in patients with advanced or metastatic solid tumors: Initial results from dose escalationJOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)Lee, JeeyunCho, Byoung ChulLee, Jae-LyunLee, Jung-YunMa, Wen WeeAdjei, Alex A.Campian, Jian LiZhao, YujieSeetharam, MaheshShim, Byoung YongYun, NariLee, Woohyung WaynePark, SujeongLee, WoosunPark, SosunKim, JaySeo, BochanKim, RyunheeJang, Myoung Ho
- [34] An open-label, phase 1a/b study of AB248, a CD8+selective IL-2 mutein fusion protein, alone or in combination with pembrolizumab in patients with advanced solid tumorsCANCER RESEARCH, 2023, 83 (08)Buchbinder, Elizabeth I.Spigel, David R.Albany, CostantineChisamore, MichaelMoynihan, Kelly D.Liu, XiaohanDelNagro, ChristopherAxt, MattPirzkall, Andrea
- [35] A phase 1/1b study of the IL-2 prodrug WTX-124 in patients with locally advanced or metastatic solid tumors after checkpoint inhibitor therapy: Initial results of the combination dose escalation with pembrolizumabJOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)Moser, Justin C.Opyrchal, MateuszRivera, Ildefonso RodriguezCurti, Brendan D.Puzanov, IgorSosman, Jeffrey A.Bilen, Mehmet AsimMorris, KristinNirschl, Christopher J.Park, SaeroBruno, MarissaWindt, PaulSubramanian, Kulandayan K.Schonborn-Kellenberger, OliverChopra, SameerIsaacs, Randi
- [36] First-in-class PD-1/IL-2 bispecific antibody fusion protein IBI363 in patients with other solid tumors: Safety and efficacy results from a phase I study.JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)Bai, XueliXu, QinLiang, XinjunChu, QianZhang, XiaochenChen, YiwenXu, NongFang, WeijiaShan, JianzhenJiang, WeiqinZhou, JianyaZheng, Yu-LongLong, SixiangChen, HaonanZhao, LiWang, HongliSun, JiyaSun, XingZhou, HuiLiang, Tingbo
- [37] Interim results of a phase 1/2 study of JNJ-63723283, an anti-PD-1 monoclonal antibody, in patients with advanced cancers.JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (05)Calvo, EmilianoMoreno, VictorFelip, EnriquetaCurigliano, GiuseppeMorgensztern, DanielGreger, JamesBae, KyounghwaMayer, Christina LourdesMarino, JenniferAttiyeh, Edward F.Xie, HongLee, James J.
- [38] FIRST-IN-HUMAN PHASE 1/2A STUDY OF THE NOVEL NONFUCOSYLATED ANTI-CTLA-4 MONOCLONAL ANTIBODY BMS-986218 ± NIVOLUMAB IN ADVANCED SOLID TUMORS: INITIAL PHASE 1 RESULTSJOURNAL FOR IMMUNOTHERAPY OF CANCER, 2020, 8 : A239 - A239Friedman, ClaireAscierto, PaoloDavar, DiwakarO'Hara, MarkShapira-Frommer, RonnieDallos, MatthewKhemka, VivekJames, LeeFischer, BruceDemes, ShilpaLi, LiKozicki, MartinRavindran, PalanikumarXu, KeKollia, GeorgiaShoukry, JacquelineYunan, MonaMassey, AshishGutierrez, Martin
- [39] A phase I open-label, dose escalation of YH003, an anti-CD40 monoclonal antibody, in combination with toripalimab (anti-PD-1 mAb) in patients with advanced solid tumorsJOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)Coward, JermaineBen MarkmanNagrial, AdnanAbed, AfafWalpole, Imogen
- [40] ARRY-382 in Combination with Pembrolizumab in Patients with Advanced Solid Tumors: Results from a Phase 1b/2 StudyCLINICAL CANCER RESEARCH, 2022, 28 (12) : 2517 - 2526Johnson, MelissaDudek, Arkadiusz Z.Sukari, AmmarCall, JustinKunk, Paul R.Lewis, KarlGainor, Justin F.Sarantopoulos, JohnLee, PatriceGolden, AdeleHarney, AllisonRothenberg, S. MichaelZhang, YuanyuanGoldman, Jonathan W.